212 related articles for article (PubMed ID: 22633690)
1. Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2.
Fuchi N; Iura Y; Kaneko H; Nitta A; Suyama K; Ueda H; Yamaguchi S; Nishimura K; Fujii S; Sekiya Y; Yamada M; Takahashi T
Bioorg Med Chem Lett; 2012 Jul; 22(13):4358-61. PubMed ID: 22633690
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines.
Suzuki Y; Cluzeau J; Hara T; Hirasawa A; Tsujimoto G; Oishi S; Ohno H; Fujii N
Arch Pharm (Weinheim); 2008 Sep; 341(9):554-61. PubMed ID: 18763715
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
5. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.
Lynch SM; DeVicente J; Hermann JC; Jaime-Figueroa S; Jin S; Kuglstatter A; Li H; Lovey A; Menke J; Niu L; Patel V; Roy D; Soth M; Steiner S; Tivitmahaisoon P; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2793-800. PubMed ID: 23540648
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
[TBL] [Abstract][Full Text] [Related]
7. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
9. 3,5-Disubstituted-indole-7-carboxamides: the discovery of a novel series of potent, selective inhibitors of IKK-β.
Miller DD; Bamborough P; Christopher JA; Baldwin IR; Champigny AC; Cutler GJ; Kerns JK; Longstaff T; Mellor GW; Morey JV; Morse MA; Nie H; Rumsey WL; Taggart JJ
Bioorg Med Chem Lett; 2011 Apr; 21(8):2255-8. PubMed ID: 21429745
[TBL] [Abstract][Full Text] [Related]
10. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
12. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.
Lin H; Yamashita DS; Zeng J; Xie R; Verma S; Luengo JI; Rhodes N; Zhang S; Robell KA; Choudhry AE; Lai Z; Kumar R; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):679-83. PubMed ID: 20005102
[TBL] [Abstract][Full Text] [Related]
13. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
[TBL] [Abstract][Full Text] [Related]
14. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
Golub AG; Bdzhola VG; Ostrynska OV; Kyshenia IV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Yarmoluk SM
Bioorg Med Chem; 2013 Nov; 21(21):6681-9. PubMed ID: 24011954
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
[TBL] [Abstract][Full Text] [Related]
20. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
